COMPARING EFFICACY OF GUSELKUMAB VERSUS USTEKINUMAB IN MODERATE TO SEVERE PSORIASIS PATIENTS : AN ADJUSTED COMPARISON BASED ON VOYAGE 1&2 AND NAVIGATE TRIALS

被引：0
|
作者：
Diels, J. [1 ]
Thilakarathne, P. [1 ]
Schubert, A. [2 ]
McElligott, S. [3 ]
机构：
[1] Janssen Cilag, Beerse, Belgium
[2] Janssen Cilag Poland, Warsaw, Poland
[3] Janssen Sci Affairs LLC, Horsham, PA USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.830
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY4
引用
收藏
页码：A544 / A545
页数：2
相关论文
共 50 条
  • [21] Efficacy responses across subgroups of patients with moderate to severe plaque psoriasis treated with Guselkumab: Results from VOYAGE 1 through 5 years
    Thaci, D.
    Foley, P.
    Puig, L.
    Merola, J. F.
    Miller, M.
    You, Y.
    Shen, Y. -K.
    Yang, Y. -W.
    Blauvelt, A.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 41 - 42
  • [22] Safety in patients with latent tuberculosis (TB) treated with guselkumab and anti-TB treatment: Voyage 1&2 trials
    Puig, L.
    Tsai, T.
    Bhutani, T.
    Uy, J.
    Ramachandran, P.
    Song, M.
    You, Y.
    Gooderham, M.
    Lebwohl, M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 81 - 81
  • [23] Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
    Blauvelt, Andrew
    Tsai, Tsen-Fang
    Langley, Richard G.
    Miller, Megan
    Shen, Yaung-Kaung
    You, Yin
    Yang, Ya-Wen
    Papp, Kim A.
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (04) : 827 - 834
  • [24] Efficacy and safety of brodalumab versus ustekinumab in obese and nonobese patients with moderate-to-severe plaque psoriasis
    Yamauchi, Paul
    Elewski, Boni
    Wu, Jashin J.
    Rastogi, Shipra
    Israel, Robert J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB119 - AB119
  • [25] TWO-YEAR EFFICACY AND SAFETY OF GUSELKUMAB FOR TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: PHASE 3 VOYAGE 1 TRIAL
    Griffiths, C. E.
    Papp, K. A.
    Kimball, A. B.
    Randazzo, B.
    Wasfi, Y.
    Li, S.
    Shen, Y. -K.
    Blauvelt, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1580 - 1581
  • [26] Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies
    Reich, K.
    Papp, K. A.
    Armstrong, A. W.
    Wasfi, Y.
    Li, S.
    Shen, Y. K.
    Randazzo, B.
    Song, M.
    Kimball, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 1039 - 1049
  • [27] Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 VOYAGE 1 study
    Blauvelt, Andrew
    Papp, Kim
    Griffiths, Christopher E. M.
    Randazzo, Bruce
    Wasfi, Yasmine
    Shen, Yaung-Kaung
    Kimball, Alexa B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
  • [28] Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials
    Blauvelt, Andrew
    Thaci, Diamant
    Papp, Kim A.
    Ho, Vincent
    Ghoreschi, Kamran
    Kim, Byung Soo
    Miller, Megan
    Shen, Yaung-Kaung
    You, Yin
    Chan, Daphne
    Yu, Jenny
    Yang, Ya-Wen
    Lebwohl, Mark G.
    Gottlieb, Alice B.
    Crowley, Jeffrey
    Foley, Peter
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (01) : 132 - 134
  • [29] Safety in patients with latent tuberculosis (TB) treated with guselkumab and anti-TB treatments in the phase 3 VOYAGE 1 and 2 trials for moderate-to-severe plaque psoriasis
    Puig, L.
    Tsai, T. -F.
    Bhutani, T.
    Uy, J.
    Ramachandran, P.
    Song, M.
    You, Y.
    Gooderham, M.
    Lebwohl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 41 - 42
  • [30] COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS ETANERCEPT USING EFFICACY RESULTS FROM PIVOTAL CLINICAL TRIALS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
    Teeple, A.
    Muser, E.
    VALUE IN HEALTH, 2018, 21 : S241 - S241
12345